Evidence Table 84. KQ2—Continuous data—Proteinuria

| **Author Year****Study Design** | **CHD Risk Category** | **CVD drug** | **Dose** | **Supplement/. Control** | **N** | **Definition of outcome** | **Post treatment Mean/****(Median)****SD/SE****Lower limit (IQR, 95% CI)****Upper Limit (IQR, 95% CI)** | **Mean change/ % change from baseline/****SD/****P Value** | **Between group differences in Means/ medians****SD/****P Value** | **Summary of Results** | **Overall Risk of Bias (ROB) Assessment** |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Ferraro 200922parallel | Unclear | ramipril | 10 | Omega-3 (EPA, DHA, or both).  | 15 | UPE (urinary protein excersion)baseline was considered a mean of the positive measurements obtained before the final period. | Mean: 367Median SD: 520SE:Lower: Upper: | Mean:% mean: -77.9Median:SD:P: | Mean:-61.6Median:SD:P:<0.01 |  | medium |
|  | No treatment (aside from CVD drug) | 15 | Mean:1353Median SD: 1304 | Mean:% mean: -11.3 |